A Randomized, Controlled, Multi-center, Phase Ⅲ Clinical Study to Investigate Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection Toripalimab (JS001) Versus Dacarbazine as the First Line Therapy for Unresectable or Metastatic Melanoma
Phase of Trial: Phase III
Latest Information Update: 24 Oct 2019
Price : $35 *
At a glance
- Drugs Toripalimab (Primary) ; Dacarbazine
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Sponsors Shanghai Junshi Biosciences
- 21 Oct 2019 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 21 Oct 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Jun 2020.
- 31 Aug 2018 Biomarkers information updated